亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

        2021-01-07 23:21:09EdwardWalshetal
        四川生理科學(xué)雜志 2021年1期

        Edward E Walsh, et al.

        Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease,coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.Multiple vaccine candidates are under development, but no vaccine is currently available.Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States.

        Methods: In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States,we randomly assigned healthy adults 18 to 55 years of age and those 65 to 85 years of age to receive either placebo or one of two lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain; or BNT162b2, which encodes a membrane-anchored SARS-CoV-2 full-length spike, stabilized in the prefusion conformation.The primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity was a secondary outcome.Trial groups were defined according to vaccine candidate, age of the participants, and vaccine dose level (10 μg, 20 μg, 30 μg, and 100 μg).In all groups but one, participants received two doses, with a 21-day interval between doses; in one group (100 μg of BNT162b1), participants received one dose.

        Results: A total of 195 participants underwent randomization.In each of 13 groups of 15 participants, 12 participants received vaccine and 3 received placebo.BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults.In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers, which were similar to or higher than the geometric mean titer of a panel of SARS-CoV-2 convalescent serum samples.

        Conclusions: The safety and immunogenicity data from this U.S.phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation.(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

        av无码精品一区二区三区四区| 久久精品国产亚洲av成人网| 亚洲一区二区日韩在线| 永久免费观看的黄网站在线| 亚洲第一狼人天堂网亚洲av| 久久久久亚洲av成人网人人网站| 中文字幕av无码免费一区| 911国产精品| 精品人妻少妇一区二区中文字幕| 久久亚洲精品国产精品婷婷| 在线国人免费视频播放| 亚洲 日本 欧美 中文幕| 中文亚洲av片在线观看| 最近中文字幕在线mv视频在线| 国产网站视频| 日本一区二区三区中文字幕视频| 精品午夜中文字幕熟女| 色狠狠一区二区三区中文| 国产午夜伦鲁鲁| 精品国产一区二区三区久久狼| 国产激情无码Av毛片久久| 国产精品很黄很色很爽的网站| 免费人成视频网站在线不卡| 无码中文亚洲av影音先锋| 久久久精品人妻一区二区三区蜜桃 | 亚洲精品国精品久久99热一| 在线观看无码一区二区台湾| 国产成人午夜av影院| 9久久婷婷国产综合精品性色 | 国产一区二区三区四色av| 久久精品国产精品国产精品污| 欧美情侣性视频| 亚洲国产精品免费一区| 伊人久久亚洲精品中文字幕| 久久国产精品偷任你爽任你| 老熟女多次高潮露脸视频| 成年人男女啪啪网站视频| 亚洲中文字幕人妻av在线| 免费大黄网站| 久久无码人妻一区=区三区| 亚洲视频在线观看青青草|